Intelligent Bio Solutions Advances Non-Invasive Fingerprint Drug Testing Toward FDA Clearance

Intelligent Bio Solutions is positioning itself as a leader in non-invasive drug screening technology with its innovative fingerprint-based detection system. The medical technology company has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, targeting a 2025 launch of its screening platform that can detect drug use through fingerprint sweat analysis.

The company's validation studies demonstrate impressive accuracy, with 94.1% precision in detecting opiates. This breakthrough technology offers significant advantages over traditional drug testing methods, providing rapid results in safety-critical work environments without invasive procedures.

Already established in 24 countries with over 450 commercial accounts, Intelligent Bio Solutions has demonstrated substantial global interest across diverse industries. The company's client base includes sectors such as logistics, mining, retail, and marine operations, highlighting the broad applicability of its drug screening technology.

The FDA's classification of the system as a Class II medical device underscores its potential reliability and scientific merit. By offering a non-invasive, quick testing method, the technology could revolutionize workplace safety protocols and drug screening practices.

As the company expands its distributor network in preparation for U.S. market entry, it represents a significant advancement in occupational health and safety technologies. The fingerprint-based screening system could provide employers with a more efficient, dignified, and technologically advanced approach to drug testing.